Healthcare product and device company Abbott Laboratories (NYSE: ABT) will be reporting earnings this Thursday before market open. Here’s what to look for.

Abbott Laboratories met analysts’ revenue expectations last quarter, reporting revenues of $11.37 billion, up 6.9% year on year. It was a mixed quarter for the company, with organic revenue in line with analysts’ estimates but revenue in line with analysts’ estimates.

Is Abbott Laboratories a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.

This quarter, analysts are expecting Abbott Laboratories’s revenue to grow 7.6% year on year to $11.8 billion, in line with the 7.2% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $1.49 per share.

Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Abbott Laboratories has missed Wall Street’s revenue estimates four times over the last two years.

Looking at Abbott Laboratories’s peers in the healthcare equipment and supplies segment, only Neogen has reported results so far. It beat analysts’ revenue estimates by 7.2%, posting year-on-year sales declines of 2.8%. The stock traded up 30.4% on the results.

Investors in the healthcare equipment and supplies segment have had steady hands going into earnings, with share prices up 1.6% on average over the last month. Abbott Laboratories is down 2.9% during the same time and is heading into earnings with an average analyst price target of $144.75 (compared to the current share price of $121.24).

When a company has more cash than it knows what to do with, buying back its own shares can make a lot of sense–as long as the price is right. Luckily, we’ve found one, a low-priced stock that is gushing free cash flow AND buying back shares. Click here to claim your Special Free Report on a fallen angel growth story that is already recovering from a setback.